SignificanceTo effectively study preclinical animal models, medical imaging technology must be developed with a high enough resolution and sensitivity to perform anatomical, functional, and molecular assessments. Photoacoustic (PA) tomography provides high resolution and specificity, and fluorescence (FL) molecular tomography provides high sensitivity; the combination of these imaging modes will enable a wide range of research applications to be studied in small animals.AimWe introduce and characterize a dual-modality PA and FL imaging platform using in vivo and phantom experiments.ApproachThe imaging platform’s detection limits were characterized through phantom studies that determined the PA spatial resolution, PA sensitivity, optical spatial resolution, and FL sensitivity.ResultsThe system characterization yielded a PA spatial resolution of 173 ± 17 μm in the transverse plane and 640 ± 120 μm in the longitudinal axis, a PA sensitivity detection limit not less than that of a sample with absorption coefficient μa = 0.258 cm − 1, an optical spatial resolution of 70 μm in the vertical axis and 112 μm in the horizontal axis, and a FL sensitivity detection limit not <0.9 μM concentration of IR-800. The scanned animals displayed in three-dimensional renders showed high-resolution anatomical detail of organs.ConclusionsThe combined PA and FL imaging system has been characterized and has demonstrated its ability to image mice in vivo, proving its suitability for biomedical imaging research applications.
Tissue heterogeneities and the presence of strong optical absorbers hinder the applications of quantitative photoacoustic imaging (PA). Having an accurate description of optical fluence distribution in heterogeneous media is essential to obtain absorption estimates. While Monte Carlo simulations and diffusion models are frequently used to approximate fluence distribution, they ignore the unique heterogeneities across imaged samples or individuals. This paper presents a method to estimate the optical fluence distributions in two-dimensional PA images applying image-based iterated corrections of the fluence map. The method was validated using a virtual tissue phantom and consecutive light transport simulations. PA images were generated synthetically, based on the true light distribution, and were subsequently used to correct the estimated fluence distribution. The correlation between the original phantom and each corrected image was measured to quantify the accuracy of the method. We found that each iteration resulted in an increase in the correlation and a qualitative improvement between the original phantom and the corrected image. This method is expected to improve the accuracy of PA imaging, especially in multi-wavelength applications and those affected by strong absorbers such as contrast agents.
We present the results on development of the 3D imaging platform combining photoacoustic tomography and fluorescence (PAFT) for preclinical and biological research. This combined multimodal imaging instrument addresses known deficiencies in sensitivity, spatial resolution, and anatomical registration of the individual imaging components. Multiangle photoacoustic projections, excited by an OPO operating in the near-infrared window, of a live anesthetized animal are used to reconstruct large volumes (30 cm3) that show deep anatomical vasculature and blood-rich tissues with resolutions exceeding 150 μm. A sCMOS camera is used for simultaneous co-registered multi-angle optical imaging. The images of a fluorescent dual-contrast agent are then reconstructed into a 3D volume using a tomographic algorithm. A separate 532-nm low-energy pulsed laser excitation is used for skin topography and imaging of superficial vasculature. All three imaging channels can be combined to produce spatially accurate in vivo volumes showing an animal’s skin, deep anatomical structures, and distribution of photosensitive molecular contrast agents. PAFT’s photoacoustic sensitivity was assessed using contrast agents in a phantom study. We demonstrate biomedical imaging application of PAFT’s combined imaging modalities by observing biodistribution of a dual-contrast agent injected intravenously to in vivo preclinical murine models.
KEYWORDS: Skin, Luminescence, Photoacoustic spectroscopy, Tissues, 3D image processing, Animal model studies, Preclinical imaging, Spatial resolution, In vivo imaging, Acquisition tracking and pointing
We report on the development of a preclinical 3D imaging platform integrating photoacoustic tomography and fluorescence (PAFT). The proposed multimodal imaging concept addresses known deficiencies in sensitivity, anatomical registration, and spatial resolution of the individual imaging modalities. Multi-view photoacoustic and optical projections of the studied animal are utilized to reconstruct large (27 cm3) volumes showing vascular network and blood-rich tissues, as well as regions with induced optical/fluorescence contrast with 3D resolution exceeding 150 μm. An additional 532-nm low-energy pulsed laser excitation is implemented as a separate imaging channel for registration over skin topography and superficial vasculature. PAFT technology enables functional and molecular volumetric imaging using wide range of fluorescent and luminescent biomarkers, nanoparticles, and other photosensitive constructs mapped with high fidelity over robust anatomical structures of the studied animal model. We demonstrated the PAFT performance using phantoms and by in vivo imaging of preclinical murine models.
We have developed a preclinical 3D imaging instrument integrating photoacoustic tomography and fluorescence (PAFT) addressing known deficiencies in sensitivity and spatial resolution of the individual imaging components. PAFT is designed for simultaneous acquisition of photoacoustic and fluorescence orthogonal projections at each rotational position of a biological object, enabling direct registration of the two imaging modalities. Orthogonal photoacoustic projections are utilized to reconstruct large (21 cm3 ) volumes showing vascularized anatomical structures and regions of induced optical contrast with spatial resolution exceeding 100 µm. The major advantage of orthogonal fluorescence projections is significant reduction of background noise associated with transmitted or backscattered photons. The fluorescence imaging component of PAFT is used to boost detection sensitivity by providing low-resolution spatial constraint for the fluorescent biomarkers. PAFT performance characteristics were assessed by imaging optical and fluorescent contrast agents in tissue mimicking phantoms and in vivo. The proposed PAFT technology will enable functional and molecular volumetric imaging using fluorescent biomarkers, nanoparticles, and other photosensitive constructs mapped with high fidelity over robust anatomical structures, such as skin, central and peripheral vasculature, and internal organs.
We introduce a preclinical imaging platform – a 3D photoacoustic/fluorescence tomography (PAFT) instrument augmented with an environmentally responsive dual-contrast biocompatible nanoprobe. The PAFT instrument was designed for simultaneous acquisition of photoacoustic and fluorescence orthogonal projections at each rotational position of a biological object, enabling direct co-registration of the two imaging modalities. The nanoprobe was based on liposomes loaded with J-aggregates of indocyanine green (PAtrace). Once PAtrace interacts with the environment, a transition from J-aggregate to monomeric ICG is induced. The subsequent recovery of monomeric ICG is characterized by dramatic changes in the optical absorption spectrum and reinstated fluorescence. In the activated state, PAtrace can be simultaneously detected by both imaging modes of the PAFT instrument using 780 nm excitation and fluorescence detection at 810 nm. The fluorescence imaging component is used to boost detection sensitivity by providing lowresolution map of activated nanoprobes, which are then more precisely mapped in 3D by the photoacoustic imaging component. Activated vs non-activated particles can be distinguished based on their different optical absorption peaks, removing the requirements for complex image registration between reference and detection scans. Preliminary phantom and in vivo animal imaging results showed successful activation and visualization of PAtrace with high sensitivity and resolution. The proposed PAFT-PAtrace imaging platform could be used in various functional and molecular imaging applications including multi-point in vivo assessment of early metastasis.
A key step in staging cancer is the diagnosis of metastasis that spreads through lymphatic system. For this reason, researchers develop various methods of sentinel lymph node mapping that often use a radioactive tracer. This study introduces a safe, cost-effective, high-resolution, high-sensitivity, and real-time method of visualizing the sentinel lymph node: ultrasound-guided photoacoustic (US/PA) imaging augmented by a contrast agent. In this work, we use clearable gold nanoparticles covered by a biocompatible polymer (glycol chitosan) to enhance cellular uptake by macrophages abundant in lymph nodes. We incubate macrophages with glycol-chitosan-coated gold nanoparticles (0.05 mg Au/ml), and then fix them with paraformaldehyde solution for an analysis of in vitro dark-field microscopy and cell phantom. The analysis shows enhanced cellular uptake of nanoparticles by macrophages and strong photoacoustic signal from labeled cells in tissue-mimicking cell phantoms consisting gelatin solution (6 %) with silica gel (25 μm, 0.3%) and fixed macrophages (13 X 105 cells). The in-vivo US/PA imaging of cervical lymph nodes in healthy mice (nu/nu, female, 5 weeks) indicates a strong photoacoustic signal from a lymph node 10 minutes post-injection (2.5 mg Au/ml, 80 μl). The signal intensity and the nanoparticle-labeled volume of tissue within the lymph node continues to increase until 4 h post-injection. Histological analysis further confirms the accumulation of gold nanoparticles within the lymph nodes. This work suggests the feasibility of molecular/cellular US/PA imaging with biocompatible gold nanoparticles as a photoacoustic contrast agent in the diagnosis of lymph-node-related diseases.
Imaging modalities utilize contrast agents to improve morphological visualization and to assess functional and molecular/cellular information. Here we present a new type of nanometer scale multi-functional particle that can be used for multi-modal imaging and therapeutic applications. Specifically, we synthesized monodisperse 20 nm Prussian Blue Nanocubes (PBNCs) with desired optical absorption in the near-infrared region and superparamagnetic properties. PBNCs showed excellent contrast in photoacoustic (700 nm wavelength) and MR (3T) imaging. Furthermore, photostability was assessed by exposing the PBNCs to nearly 1,000 laser pulses (5 ns pulse width) with up to 30 mJ/cm2 laser fluences. The PBNCs exhibited insignificant changes in photoacoustic signal, demonstrating enhanced robustness compared to the commonly used gold nanorods (substantial photodegradation with fluences greater than 5 mJ/cm2). Furthermore, the PBNCs exhibited superparamagnetism with a magnetic saturation of 105 emu/g, a 5x improvement over superparamagnetic iron-oxide (SPIO) nanoparticles. PBNCs exhibited enhanced T2 contrast measured using 3T clinical MRI. Because of the excellent optical absorption and magnetism, PBNCs have potential uses in other imaging modalities including optical tomography, microscopy, magneto-motive OCT/ultrasound, etc. In addition to multi-modal imaging, the PBNCs are multi-functional and, for example, can be used to enhance magnetic delivery and as therapeutic agents. Our initial studies show that stem cells can be labeled with PBNCs to perform image-guided magnetic delivery. Overall, PBNCs can act as imaging/therapeutic agents in diverse applications including cancer, cardiovascular disease, ophthalmology, and tissue engineering. Furthermore, PBNCs are based on FDA approved Prussian Blue thus potentially easing clinical translation of PBNCs.
A key step in staging cancer is the diagnosis of metastasis that spreads through lymphatic system. For this reason, researchers develop various methods of sentinel lymph node mapping that often use a radioactive tracer. This study introduces a safe, cost-effective, high-resolution, high-sensitivity, and real-time method of visualizing the sentinel lymph node: ultrasound-guided photoacoustic (US/PA) imaging augmented by a contrast agent. In this work, we use clearable gold nanoparticles covered by a biocompatible polymer (glycol chitosan) to enhance cellular uptake by macrophages abundant in lymph nodes. We incubate macrophages with glycol-chitosan-coated gold nanoparticles (0.05 mg Au/ml), and then fix them with paraformaldehyde solution for an analysis of in vitro dark-field microscopy and cell phantom. The analysis shows enhanced cellular uptake of nanoparticles by macrophages and strong photoacoustic signal from labeled cells in tissue-mimicking cell phantoms consisting gelatin solution (6 %) with silica gel (25 μm, 0.3%) and fixed macrophages. The in-vivo US/PA imaging of cervical lymph nodes in healthy mice (nu/nu, female, 5 weeks) indicates a strong photoacoustic signal from a lymph node 10 minutes post-injection (2.5 mg Au/ml, 80 μl). The signal intensity and the nanoparticle-labeled volume of tissue within the lymph node continues to increase until 4 h post-injection. Histological analysis further confirms the accumulation of gold nanoparticles within the lymph nodes. This work suggests the feasibility of molecular/cellular US/PA imaging with biocompatible gold nanoparticles as a photoacoustic contrast agent in the diagnosis of lymph-node-related diseases.
While molecular and cellular imaging can be used to visualize the conventional morphology characteristics of vulnerable plaques, there is a need to monitor other physiological factors correlated with high rupture rates; a high M1 activated macrophage concentration is one such indicator of high plaque vulnerability. Here, we present a molecularly targeted contrast agent for intravascular photoacoustic (IVPA) imaging consisting of liposomes loaded with indocyanine green (ICG) J-aggregates with high absorption at 890 nm, allowing for imaging in the presence of blood. This “Lipo-ICG” was targeted to a biomarker of M1 activated macrophages in vulnerable plaques: folate receptor beta (FRβ). The targeted liposomes accumulate in plaques through areas of endothelial dysfunction, while the liposome encapsulation prevents nonspecific interaction with lipids and endothelium. Lipo-ICG specifically interacts with M1 activated macrophages, causing a spectral shift and change in the 890/780 nm photoacoustic intensity ratio upon breakdown of J-aggregates. This sensing mechanism enables assessment of the M1 activated macrophage concentration, providing a measure of plaque vulnerability. In a pilot in vivo study utilizing ApoE deficient mouse models of atherosclerosis, diseased mice showed increased uptake of FRβ targeted Lipo-ICG in the heart and arteries vs. normal mice. Likewise, targeted Lipo-ICG showed increased uptake vs. two non-targeted controls. Thus, we successfully synthesized a contrast agent to detect M1 activated macrophages in high risk atherosclerotic plaques and exhibited targeting both in vitro and in vivo. This biocompatible agent could enable M1 macrophage detection, allowing better clinical decision making in treatment of atherosclerosis.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.